TapImmune President Dr. John Bonfiglio to Present at BioNetwork Partnering Summit on October 5, 2016

Oct 05, 2016, 08:00 ET from TapImmune Inc.

JACKSONVILLE, Florida, October 5, 2016 /PRNewswire/ --

TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced its President and Chief Operating Officer, Dr. John Bonfiglio, will be a speaker and deliver a corporate presentation at the BioNetwork Partnering Summit on Wednesday, October 5 at 4:35 PM PT. The conference will take place at the Ritz-Carlton in Laguna Niguel, California on October 5-7, 2016.

Dr. Bonfiglio will speak on the first day of the event focused on "The Latest Trends in Biopharma Partnering." TapImmune collaborations with organizations including the Mayo Clinic and the U.S. Department of Defence, Memorial Sloan Kettering and AstraZeneca will be discussed.

Conference attendees seeking a one-on-one meeting with Dr. Bonfiglio may contact TapImmune directly, or contact BioNetwork West.

About TapImmune Inc. 

TapImmune Inc. is an immune-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastatic disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at http://www.tapimmune.com for details.

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most

recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO

SOURCE TapImmune Inc.